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Abstract
Cervicovaginal fluid has an important function in the homeostasis and immunity of the lower female genital tract.
Analysis of the cervicovaginal fluid proteome may therefore yield important information about the pathogenesis of
numerous gynecological pathologies. Additionally, cervicovaginal fluid has great potential as a source of biomar-
kers for these conditions.
This review provides a detailed discussion about the human cervicovaginal proteome and the proteomics studies
performed to characterize this biological fluid. Furthermore, infection-correlated pathological conditions of the
female genital tract are discussed for which cervicovaginal fluid has been used in order to identify potential bio-
markers. Recent years, numerous studies have analyzed cervicovaginal fluid samples utilizing antibody-based tech-
nologies, such as ELISA or Western blotting, to identify biomarkers for preterm birth, premature preterm rupture of
membranes, bacterial vaginosis and cervical cancer. The present article will discuss the importance of proteomic
technologies as alternative techniques to gain additional meaningful information about these conditions. In addi-
tion, the review focuses on recent proteomic studies on cervicovaginal fluid samples for the identification of
potential biomarkers. We conclude that the use of proteomic technology for analysis of human cervicovaginal fluid
samples is promising and may lead to the discovery of new biomarkers which can improve disease prevention and
therapy development.
Female genital tract physiology
The female genital tract is characterized by a unique
immunologic micro-environment. It is essential for
human reproduction that the immune system of the
female genital tract is modulated correctly as it needs to
tolerate the presence of sperm and fertilized oocytes
without starting an immune reaction. Nevertheless, a
strong immune system in the genital tract is very impor-
tant to protect the interior organs and the fetus or
embryo against the large pathogenic stress [1]. This obli-
gation of a dual immune system, one that tolerates and
one that reacts efficiently, is a biological challenge. Fail-
ure to successfully accomplish this challenge can lead to
specific gynecopathological conditions which eventually
may result in severe complications.
The lower female genital tract (vagina and ectocervix)
is lined with a protective non-keratinized stratified squa-
mous epithelium, whereas the higher genital tract
(uterus, oviducts and ovaria) is lined with a columnar
epithelium connected with tight junctions. The mucosa
creates a physical barrier for invading microorganisms
due to the production of a glycocalyx (i.e. a hydrophilic
glycoprotein layer) which allows for hydration of the
mucosa which hinders the adherence of bacteria on
epithelial cells. Nevertheless, when bacteria are able to
reach the mucosa and adhere to it, they will be removed
by cell shedding [1-8].
The mucosa of the lower female genital tract is cov-
ered by numerous commensal bacteria which form an
important protective factor. The normal vaginal bacterial
flora consists predominantly of Lactobacillus spp.
(e.g. Lactobacillus jenensii, Lactobacillus crispatus, Lac-
tobacillus iners) but (facultative) anaerobic species such
as Gardnerella vaginalis are also present although in
much lower concentrations. Glycogen from exfoliated
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any medium, provided the original work is properly cited.cells is first metabolized to glucose by epithelial cells
which is then used by the vaginal flora to produce lactic
acid, thereby maintaining a low vaginal pH (3.5-4.7).
Also, some Lactobacillus spp. (e.g. Lactobacillus crispa-
tus, Lactobacillus rhamnosus and Lactobacillus acido-
philus)p r o d u c eH 2O2 at concentrations lethal for
exterior microorganisms. Additionally, commensals
compete with nonresident bacteria for available nutri-
ents and some bacteria produce broad-spectrum antimi-
crobial peptides (i.e. bacteriocins). Together, these
factors exert a selective antimicrobial activity which
inhibits the growth of nonresident bacteria without
affecting the survival of the commensal flora [1,2,7,9-11].
The presence of adaptive immunity mechanisms in the
female genital tract is known, although detailed informa-
tion is scarce. Langherhans (dendritic) cells, which
reside in the genital mucosa, and epithelial cells are able
to present antigens to T lymphocytes and thus can elicit
an adaptive immune response [3,12]. Also, plasma cells
are localized nearby submucosal glands and secrete,
after activation, immunoglobulins (primarily IgG and
secretory IgA) into the cervicovaginal fluid (CVF; see
below). These immunoglobulins can recruit and activate
other immune cells, hinder bacterial adherence and
opsonize pathogens. Additionally, mucosal-associated
lymphoreticular tissue (MALT), which consists mainly
of T-lymphocytes and monocytes/macrophages, is
located in the lamina propria of the cervix [2].
Another vital element of the immune system of the
female genital tract is CVF. CVF is made of (i) vulvar
secretions from sebaceous, sweat, Bartholins and Skene
glands, (ii) plasma transudate through the vaginal wall,
(iii) exfoliated cells, (iv) bacterial products, (v) cervical
mucus (vi) endometrial and oviductal fluids and
(vii) secretions from vaginal immune cells. The latter
three are influenced by sex steroid hormones e.g. during
the menstrual cycle and pregnancy [13,14]. CVF consists
mainly of water and contains many different factors
such as cholesterol, lipids, mucin, carbohydrates, amino
acids, proteins and inorganic ions. It covers the lower
female genital tract and hydrates the mucosa, creating a
physical barrier for microbial invasion.
Many studies have used CVF as samples for the analy-
sis of proteins and found correlations between different
expression profiles and specific pathologies. It is there-
fore not surprising that during the last 5 years several
comprehensive proteomics studies have been performed
on CVF in order to catalogue the CVF proteome and to
look for potential biomarkers.
Cervicovaginal fluid as potential biomarker
source
Over the last 10 years, the potential of using body fluid
for the identification of diagnostic or prognostic
b i o m a r k e r sh a sb e e nr e c o g n i z e d[ 1 5 ] .T h i si sa l s ot h e
case for CVF, where the low cost and ease of sample
collection, circumvention of the risk associated with
biopsies and the possibility of observing high numbers
of patients using multiple samples are clear advantages
of this body fluid [16-18]. Four different methods are
frequently applied for the collection of CVF: 1) cervi-
covaginal washings (i.e. the cervicovagina is rinsed with
washing buffer after which the fluid is collected), 2) cer-
vicovaginal swabs (i.e. swabs or brushes are applied to
the mucosal wall and rotated to collect the CVF), 3) cer-
vicovaginal wicks (i.e. wicks such as tampons, strips or
sponges are inserted in the female genital tract which
absorb cervicovaginal secretions) and 4) diaphragm-like
devices (i.e. cups placed over the cervix which collect
cervical fluid). Few studies have been performed on the
reliability and validity of the CVF collection methods.
Snowhite et al. [19] compared the wicking method with
cervicovaginal washings and found that cervicovaginal
washings are the superior sample collection method for
cytokine assays in terms of reproducibility. Another
research group demonstrated that cervicovaginal wash-
ings are better samples as compared to swabs for assess-
ment of HIV1 RNA in cervicovaginal secretions [20].
Lastly, collection of samples using cups has the advan-
tage that ready-to-use samples are obtained. Because the
secretions are not absorbed (cfr. swabs and wicks), no
sample recovery steps need to be undertaken and pro-
tein loss is minimized. In addition, the cervical secre-
tions are not diluted in a washing buffer during sample
collection (cfr. cervicovaginal washings). However,
because the cups are placed over the cervix, this sample
collection method has the disadvantage that only cervi-
cal secretions and no vaginal secretions are collected.
These examples indicate that the sample collection
method may influence results. Therefore, well defined
and standardized sampling methods may help avoiding
misinterpretation of results and decrease the technical
variation of the experimental setup.
So far, plasma/serum is the most analyzed body fluid
compared to other body fluids such as cerebrospinal
fluid, urine, saliva, bronchoalveolar lavage fluid, nipple
aspirate fluid, tear fluid and amniotic fluid [18]. A great
advantage of plasma/serum is that these samples contain
a plethora of potential biomarkers since this body fluid
is in contact with nearly all organ systems. Nevertheless,
some important disadvantages are inherent to the use of
plasma/serum. Due to the presence of plasma/serum in
t h ee n t i r eb o d y ,b i o m a r k e r soften lack discriminatory
power for a particular organ system and thus are not
specific enough. Also, since the volume of plasma/serum
is substantial, potential biomarkers are strongly diluted,
resulting in lowered sensitivity. Moreover, it is well
known that serum and plasma protein concentrations
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sive sample preparation and separation steps. All
together, these disadvantages result in a large inter- and
intravariability of plasma/serum samples [16].
Other body fluids such as cerebrospinal fluid, urine or
CVF are less subjected to these restraints. For instance,
it can be expected that biomarkers found in CVF, being
a “proximal” fluid, show more specificity and sensitivity
for gynecopathological conditions as compared to blood
[21]. This is due to 1) the relatively small volume/organ
ratio of CVF, thereby increasing the possibility that
potential biomarkers are less diluted, thus increasing
their sensitivity and 2) CVF is a body fluid that is speci-
fic for the female genital tract and hence the CVF pro-
teome will be related to conditions of these organs
[16,18,21,22]. CVF is therefore an interesting body fluid
to use for the development of biomarkers for gynecolo-
gical pathologies. One must keep in mind however that
many factors may significantly influence the protein
composition of the CVF. For example, secretions of the
genital tract are notably influenced by varying levels and
ratios of estrogens and progesterone during the men-
strual cycle [23] resulting in variable amounts of protein
yield (for instance, we measured between 0.58 mg and
13.37 mg in cervicovaginal washings). Therefore it is
practically impossible to quantify the normal amount of
total protein content in healthy CVF. Although one can
expect some changes in the amount of protein content
for pathological conditions, these are often unnoticeable
due to the large normal fluctuations. Because of this
variation, it is often difficult to distinguish real biomar-
kers from natural occurring biophysiological variations
[16,24]. For example, analysis of microbicide induced
cytokine deregulation is often hindered by the menstrual
cycle [4,25-27], pathological conditions, sexual inter-
course [28], age [29], and the use of contraceptives
[30-33] or hormonal substitution therapies. If one disre-
gards these effects, they will inevitably lead to biased or
confounded results. The use of experimental designs of
high-quality and well determined and clinically validated
criteria are required to detect real product induced cyto-
kine changes from background levels [34].
The use of body fluid as biomarker source implies the
application of proteomic methodologies, because body
fluids do not contain a corresponding genome or tran-
scriptome and therefore gene expression cannot be ana-
lyzed [17]. Most studies on the identification of potential
biomarkers are restricted to the use of antibody depen-
dent techniques (e.g. ELISA or Western blotting). Thus
far, only a limited number of large proteomic studies
have been performed on CVF and the majority of these
studies focused on the characterization of the CVF pro-
teome. Only during the last few years quantitative
methods were used to detect differences in protein
profiles between particular conditions [14,22,35-45].
Proteomics techniques for the characterization of
the human cervicovaginal proteome
Generally, a proteomic biomarker study can be divided in
several steps which are critical to obtain clinically and sta-
tistically significant results. (i) The characterization and
analysis of the proteome, which also includes analysis of
variation, is a first essential stage followed by (ii) differen-
tial analysis of the proteome, including statistical analysis
to identify potential biomarkers (discovery phase). In a
next phase (iii) the potential markers need to be validated
on other independent cohorts (validation phase) after
which (iv) the implementation possibilities of the validated
markers in a clinical environment can be investigated
[16,18]. Only the last 5 years, studies started to investigate
the human CVF proteome to characterize the protein
composition and to detect protein expression differences
between specific patient conditions (table 1) using com-
prehensive antibody-independent proteomics techniques.
Venkataraman et al. [38] published one of the first
human CVF proteomics papers and demonstrated that
human CVF may play a critical role in the host defense
against HIV. The authors showed that CVF contained
intrinsic anti-HIV activity from which the greater part
was found in the cationic protein/peptide fraction. This
fraction was analyzed using two-dimensional (native
acid urea-PAGE followed by Tricine SDS-page) gel elec-
trophoresis after which spots were identified using
MALDI-TOF/TOF tandem mass spectrometry. The
authors identified 18 polypeptides including known anti-
microbial peptides/proteins such as calgranulin A/B,
lysozyme, human neutrophil peptide (HNP) 1, cathepsin
G and several histones [2]. However, none of these
cationic polypeptides alone had potential anti-HIV activ-
ity. In addition, cationic fraction-depleted CVF did not
contain anti-HIV activity but this activity was comple-
tely restored after adding the isolated cationic fraction.
This indicates that the anti-HIV activity is almost
entirely dependent on the CVF cationic fraction and
probably is the result of a synergistic combination of dif-
ferent molecules. Also, it can be expected that, apart
from the 18 proteins identified in this study, the cationic
fraction from CVF is constituted of other proteins and
peptides (such as elafin, see later) which could also play
a role in the anti-HIV activity from CVF.
Di Quinzio et al. [40] used full human CVF instead of a
particular fraction for their proteomics analysis. Cervicova-
ginal swabs from five pregnant women were collected and
separated using 2D (isoelectric focusing (IEF) followed by
SDS-PAGE) gel electrophoresis. Subsequently, protein
spots common to all five gels were tryptically digested and
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tively, the samples were first separated using capillary
reversed phase (RP)-HPLC followed by electrospray ion
trap tandem mass spectrometry. The authors identified 15
different proteins common to the five samples. These pro-
teins function in different areas such as blood transport,
structural integrity, fatty acid metabolism, calcium bind-
ing, inflammation, proteinase inhibition and oxidative
stress defense [40]. The group further developed their pro-
teomics platform to allow the analysis of differences in the
CVF proteome caused by normal labour and pregnancy.
In a first study, the authors compared the 12-29kDa CVF
proteome fraction from pregnant women at 26-30 days
before labour onset, 1-3 days before onset and during nat-
ural term labour. They identified seven different proteins
(cystatin-A, interleukin-1 receptor antagonist, glutathione
S-transferase P, peroxiredoxin-2, thioredoxin, copper-zinc
superoxide dismutase, and epidermal fatty-acid binding
protein) [39]. In a follow-up study, interleukin-1 receptor
antagonist (IL-1RA), was validated and shown to decrease
in concentration during the course of the pregnancy. Also,
the concentrations of IL-1RA were 6-fold lower in case of
preterm premature rupture of membranes (see below),
which indicates that IL-1RA functions in the remodeling
of the fetal membranes [46]. Furthermore, the group used
the same techniques to analyze the 25-45 kDa human
CVF proteome fraction and compared expression profiles
between pregnant women at 14-17 days, 7-10 days and 0-
3 days before natural labour and during labour. The
authors found temporal changes in the expression of five
proteins (serpin B3, serpin B1, annexin A3, collagen a2
type IV and albumin) which correlate with natural occur-
ring term labour [47]. Recently, the same research group
showed that 1) expression of a-enolase was significantly
increased during spontaneous labour at term [48] and 2)
parturition results in increased oxidative stress. This last
phenomenon was reflected in the CVF since the total anti-
oxidant capacity of CVF decreased drastically during
labour, largely due to a decline in copper zinc superoxide
dismutase and thioredoxin-4 CVF concentrations. The
combination of total antioxidant capacity of CVF and cop-
per zinc superoxide dismutase concentration showed high
specificity and sensitivity for the prediction of labour
within three days [49]. These studies are good examples of
how proteomics may yield important information about
complex biological phenomena such as pregnancy.
Although the studies from Venkataraman et al. [38]
and Di Quinzio et al. [40] were among the first to use
proteomics techniques to mine the CVF proteome, their
analyses were restricted to analysis of CVF proteome
subfractions. In contrast, Dasari et al. [42] performed
the first large comprehensive analysis of the CVF pro-
teome. The authors used 2D (strong cation exchange
(SCX) followed by RP)-HPLC or SDS-PAGE followed by
RP-HPLC as sample separation methods. CVF proteins
or peptides were identified using ESI-Q/TOF tandem
mass spectrometry combined with several search
engines. The study primarily aimed to identify CVF pro-
teins and 150 different proteins were detected of which
the majority functioned either as immune and defense-
related or as metabolic proteins. The authors also com-
pared serum and amniotic fluid protein sets with the
Table 1 Overview of primarily qualitative proteomic studies performed on human CVF and cervical mucus
Study Samples Separation method MS method
Venkataraman et al.,
2005[38]
Undiluted CVF collected in cup from healthy women
(postmenarcheal, pre-menopausal)
2D-PAGE (1D: AU-PAGE; 2D: Tricine- SDS-
PAGE)
MALDI-TOF-TOF
Di Quinzio et al., 2007
[40]
Swabs from pregnant women (37 weeks gestation) 2D-PAGE (1
st D: IEF; 2
nd D SDS-PAGE)
followed by RP-LC
MALDI-TOF or
ESI-linear IT
Dasari et al., 2007[42] Swabs from pregnant women (18,5 weeks gestation as
mean)
1D-SDS-PAGE followed by offline 2D(SCX/
RP)-LC
ESI-Q-TOF
Tang et al., 2007[45] Washings from clinically normal women; 7 washings from
women infected with Candida spp.
2D-PAGE (1
st D: IEF; 2
nd D SDS-PAGE) MALDI-TOF-TOF
Shaw et al., 2007[44] Gauze from healthy women 1D-SDS-PAGE or SCX-LC both followed by
RP-LC
ESI-linear IT
Pereira et al., 2007[43] Swabs from pregnant women (15.8-35.9 weeks gestation) 2D-DIGE or MudPIT(SCX/RP)-LC ESI-Q-TOF
Andersch-Björkman et
al., 2007[36]
Cervical aspiration using syringe from healthy women 1D-PAGE or SDS-agarose electrophoresis
followed by RP-LC
ESI-FT-ICR
Klein et al., 2008[14] Swabs from pregnant women (30.5 weeks gestation as
mean)
RP-LC ESI-IT
Zegels et al., 2009[22] Washings from HPV-infected women Ultrafiltration or C4-LC protein fractionation/
C18-LC peptide separation
MALDI-TOF-TOF
Panicker et al., 2010
[37]
Cervical mucus from healthy women obtained with
sponges
2D-PAGE (1
st D: IEF; 2
nd D SDS-PAGE) or 1D-
PAGE followed by RP-LC
ESI-Q-TOF
For each study the following information is presented: 1) the nature of the samples which were used in the study (sample collection method and patient
physiology), 2) the methods used to separate proteins and peptides and 3) MS method used for analysis.
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to CVF, whereas 56 proteins were also found in serum
and 17 in amniotic fluid. Additionally, they found that
there is a significant degree of complementarity between
the experimental setups as well as between the different
search engines (Sequest, X!Tandem and OpenSea) used
for the identification of CVF proteins. For example, only
38% of the spectra were identified by all three search
engines, indicating that implementation of different
search algorithms can result in a significant increase in
number of identifications. Finally, the authors empha-
sized the need for biological and technical replicates in
o r d e rt oi d e n t i f ya sm a n yp r o t e i n sa sp o s s i b l ef r o mt h e
CVF proteome [42].
The same research group published the first compara-
tive quantitative proteomics study on CVF. Pereira et al.
[43] used 2D (IEF followed by SDS-PAGE) differential
gel electrophoresis (2D-DIGE) to analyze differences in
CVF protein expression levels between women with pre-
term-labour, spontaneous preterm birth patients and
controls. Alternatively, they performed also 2D (SCX
followed by RP) HPLC followed by ESI-Q/TOF to iden-
tify present proteins and to quantify protein expression
semiquantitatively using spectral counting. During these
experiments, the authors identified 205 proteins. Of
those, 28 (2D-LC-MS/MS analysis) and 17 (2D-DIGE)
proteins showed statistically significant changes between
preterm labour patients, patients with spontaneous pre-
term birth and controls which can be considered as
potential biomarkers [43]. This study is further dis-
cussed in more detail below.
Tang et al. [45] also performed a characterization of
the CVF proteome using 2D (IEF followed by SDS-
PAGE) gel electrophoresis and MALDI-TOF/TOF analy-
sis for the identification of CVF proteins. 59 different
proteins were thus identified. The authors showed the
presence of polymorphonuclear cells (e.g. neutrophils
and eosinophils) in CVF and demonstrated that these
immune cells could be activated and secreted proteins
in the lower genital tract. Additionally, they showed that
CVF contains a large fraction (47%) of proteins which
are also found in plasma, which could be indicative for
the permeability status of genital tract mucosa. Since
the permeability is often increased in case of cervicova-
ginal infection, these plasma proteins could eventually
be used together with secreted proteins from activated
neutrophils and eosinophils (e.g. lactoferrin, myeloper-
oxidase, human neutrophil lipocalin and eosinophilic
cationic protein) as markers for cervicovaginal inflam-
mation [45].
The proteomics study which resulted in the largest set
of protein identifications was performed by Shaw et al.
[44]. The authors were able to identify 685 proteins
from human CVF by means of 2D (SCX followed by
RP)-HPLC and SDS-PAGE followed by RP-HPLC. Tan-
dem mass spectrometric analysis was executed using an
ESI-linear ion trap after which proteins were identified
and functionally classified. Due to the complementary
nature of the techniques and the incorporation of sev-
eral technical replicates the authors were able to identify
a large number of CVF proteins. Also, a less stringent
identification methodology was used in this study, which
may also account for this high number. Additionally, the
authors focused on the kallikrein family (i.e. family of 15
secreted serine proteases with tryptic or chymotryptic
activity) and confirmed the presence of different kallik-
reins (kallikrein 6, 7, 10, 11, 12 and 13) in CVF by
ELISA [44]. Further research on this topic by the same
authors revealed that kallikreins may play a physiologi-
cally active role in the desquamation of vaginal epithelial
cells and activation of cervicovaginal antimicrobial pro-
teins. The authors also hypothesized that cervicovaginal
kallikrein expression may result in pathological condi-
tions (e.g. PPROM) [50,51].
Klein et al. [14] performed proteome analyses on CVF
samples from pregnant women who had symptoms of
pending preterm birth. The authors identified 40, mainly
high abundant, proteins using a shotgun proteomics
approach using nanoscale RP-HPLC coupled to an ESI-
ion trap mass spectrometer and showed that this
method yields reproducible and reliable results. Addi-
tionally, they analyzed CVF using 2D-PAGE and demon-
strated that the 2D-PAGE profiles are very similar for
different samples, but that the spot intensities showed a
certain degree of intersample variation.
Our group [22] also used proteomics technology to
characterize the CVF proteome. During a colposcopy,
the cervicovagina is rinsed with a 5% acetic acid solution
in order to make HPV infected lesions visible. Normally,
this washing fluid is discarded but was used by our
g r o u pt op e r f o r mC V Fp r o t e o m i c ss t u d i e s .U s i n gC 4-
RP-HPLC fractionation on the protein level followed by
C18-RP-HPLC on the peptide level, and MALDI-TOF/
TOF mass spectrometry, we were able to identify 339
proteins. During these experiments, we also determined
the technical variability of the platform. Three technical
replicates were analyzed and 68% of the different pro-
teins identified, were detected in all three replicates.
Analysis of the chromatographic separations showed a
high degree of reproducibility (coefficient of variation
was 0.56%). This led to the conclusion that the largest
contribution to the technical variation is made by the
mass spectrometric analysis. Also, using an in-house
build relational database, we compared the largest pro-
teomics studies on CVF and determined a set of pro-
teins which are identified in the vast majority of the
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tical methods. This overlapping protein set was the first
step towards the delineation of the CVF core proteome
(see below) [22].
Finally, two studies have been performed on cervical
mucus [36,37]. Because cervical mucus is part of the CVF
(see above), these studies can be seen as an analysis of a
subfraction of the CVF proteome. Andersch-Björkamn
et al. [36] used 1D-PAGE and SDS-agarose composite gel
electrophoresis to separate proteins and subsequently
performed RP-nano-HPLC peptide separations. Peptides
were identified using ESI-FTICR tandem mass spectro-
metry. The authors identified 178 proteins from cervical
mucus. Furthermore, they analyzed protein and mucin
composition and the mucin O-glycosylation of the cervi-
cal mucus at different time points during the menstrual
cycle. The results showed that cervical mucus was similar
before and after ovulation, but differed at the time of
ovulation. This observation was also seen in alterations
of the O-glycosylation of the mucus. The physiological
significance of these changes is not yet understood [36].
Panicker et al. [37] recently performed a study on the
human cervical mucus proteome. The authors used
2D-PAGE and 1D-PAGE followed by nanocapillary
RP-HPLC. Tandem mass spectrometry was performed
using an ESI-Q-TOF to characterize the cervical mucus
proteome. Immunodepletion of albumin and immuno-
globulins did not result in a significant improvement.
Although the authors noticed an overlap between the
different experimental setups, each platform yielded a
certain amount of unique proteins, indicating the impor-
tance of using different techniques in order to maximize
proteome coverage. The authors also characterized the
phosphorylation and glycosylation of cervical mucus pro-
teins and found 14 proteins which were posttranslation-
ally modified [37].
The studies described above primarily aimed to catalo-
gue the CVF proteome. Therefore, in what follows,
some upcoming facts of the CVF proteome will be
reviewed in more detail. Beside these studies, four pro-
teomic studies on CVF have been performed which
focused on the detection of differences in protein
expression profiles due to HIV resistance and pending
preterm birth [35,41,52,53]. These quantitative studies
are discussed further below.
The cervicovaginal proteome: numbers and facts
852 different proteins were identified in diverse antibody-
independent proteomics studies on human CVF
and cervical mucus (listed in additional file 1) [14,22,
36-38,40,42-45]. Also, during our latest experiments we
were able to identify an additional 256 CVF proteins
(unpublished data), making it a total of 1108 different
CVF proteins which are identified thus far (listed in
additional file 2). 252 and 257 proteins were also found in
respectively plasma [54,55] and amniotic fluid [56-58]
(shown in additional file 2). 733 proteins from the CVF
proteome were not identified in plasma or amniotic fluid.
Additionally, 223 proteins were identified in cervical
mucus [36,37]. Of those, 51 proteins were uniquely
identified in cervical mucus (additional file 2) while the
greater part (172 proteins) was also identified in studies
on CVF [14,22,38,40,42-45]. This was to be expected
because cervical mucus is a subfraction of CVF. This
s u g g e s t st h a ta n a l y s i so fs u b f r a c t i o n so ft h eC V Fp r o -
teome may still yield new identifications [22].
Functional classification (Figure 1A) of the CVF pro-
teome shows a great diversity of biological roles of
which “protein metabolism and modification” and
“immunity and defense” are the largest categories
(respectively 17% and 10%). Classification based upon
cellular localization (Figure 1B) shows that most pro-
teins are present in the cytoplasm or in the extracellular
region (respectively 21% and 20%)
Figure 2 gives a schematic overview of the proteome
structure of the CVF. Although exceptions and devia-
tions from this generalized scheme are most likely, it
may help in explaining the difficulties encountered dur-
ing CVF biomarker discovery. Roughly, a proteome con-
sists of a plethora of proteins which are present in
either higher concentrations (hence easier to identify) or
lower concentrations (usually difficult to identify). The
difference between the highest and the lowest protein
concentration in a proteome is described as the dynamic
range, which is specific for a particular sample and
important to take into account when performing com-
prehensive proteomics studies. Indeed, the higher the
dynamic range of the sample, the more difficult it is to
describe its proteome as complete as possible. Imple-
mentation of different separation dimensions, optimiza-
tion of the techniques and sample preparation may
increase the sensitivity and resolving power of the pro-
teomics platform, thus allowing the detection of more
proteins.
Because CVF is an extracellular fluid with an important
role in the innate immunity, it can be expected that phy-
siological relevant proteins are extracellular, immunologi-
cal molecules. We call these “characteristic” proteins
since, based on their function and localization, they
represent the fundamental characteristics of CVF. Both
high and low abundant CVF proteins may fulfill a physio-
logical function in the cervicovagina. For example, we
found that the most abundant protein in CVF is S100A9
[22] which forms with S100A8 the calprotectin heterodi-
mer. Calprotectin is a potent cervicovaginal antimicrobial
peptide and inhibits bacterial growth by sequestration of
zinc. Its importance is also reflected in the numerous
physiological and pathological processes (e.g. cervical
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have been found with differences in calprotectin expres-
sion levels [59]. Examples of low abundant physiological
relevant proteins are b-defensins or histones. In response
to infectious stimuli, histones can create neutrophil extra-
cellular traps (NET) (i.e. protrusions made of a DNA
backbone in which histones, proteases and antimicrobial
peptides/proteins are embedded) which are efficient in
trapping and eliminating pathogens [60-62].
However, a substantial fraction of high and low abun-
dant proteins may also originate from aberrant pro-
cesses. For instance, sampling of CVF may cause
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Page 7 of 23disruption of the epithelial cell layer (e.g. when using
brushes or tampons) and the continuous shedding of
the epithelial cell layer may also bring in dead cells.
These processes introduce many intracellular proteins
(e.g. metabolic or cytoskeletal proteins) in the CVF
which have no significant biological function in this
body fluid. We therefore call these proteins “non-char-
acteristic” since their function and localization do not
match the CVF related characteristics.
In general, it can be assumed that due to the extracel-
lular nature of the CVF and its importance in the innate
immunity, the characteristic proteins will contain larger
amounts of extracellular and immunological fractions as
compared to the non-characteristic proteins.
Another part of the CVF is made of non-characteristic
low abundant proteins of which the concentration
shows large intra- and interindividual variations. These
concern often intracellular proteins which take part in
metabolic processes (e.g. glycolysis).
Although the higher abundant characteristic proteins
may contain very interesting biomarkers, potential bio-
markers usually reside in the lower abundant part of the
proteome. Therefore, one of the main challenges is the
isolation of the biomarker from the numerous surround-
ing background proteins. How can these two be dis-
tinguished? Since background proteins are usually
sporadically and randomly detected, they show no corre-
lation with a particular physiological or pathological
condition. In contrast, there must be a clear and signifi-
cant association between alterations in the concentration
of a biomarker and a specific condition or pathology.
Taking all of the above into account, the CVF pro-
teome can roughly be divided into two subfractions: the
core and the variable proteome. The core proteome
consists of proteins which are identified in most proteo-
mics studies and therefore mainly represents high abun-
dant (characteristic and non-characteristic) proteins,
although characteristic low abundant proteins are also
present. Hence, we expect the fraction of characteristic
proteins to be high in the core proteome. We recently
described a set of 136 proteins which are frequently
identified, independent of patient physiology or used
analytical methods. This subproteome has an increased
extracellular immunological protein fraction [22], indi-
cating that it is more relevant for CVF (as compared to
the complete set of overlapping and non-overlapping
proteins). It can therefore be considered as a first ver-
sion of the core proteome. In contrast, the variable
proteome contains proteins which are infrequently iden-
tified and often represent non-characteristic low abun-
dant proteins. Therefore, the extracellular and
immunological fraction is decreased in this part.
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• High%extracellular
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Figure 2 Schematic overview of the CVF proteome composition. The CVF proteome can be roughly divided into “higher” and “lower”
abundant proteins. The proteins from these categories can be further subdivided based on their function and cellular localization. The term
“characteristic” is used here for proteins with a function and cellular localization which is representative for the functions of CVF. “Non-
characteristic” is used for proteins which presumably do not have a measurable or known significant biological function in this body fluid. For
each category, a general indication of the percentage immunological and extracellular is given. Proteins from the subcategories subsequently
construct the “core” and “variable” proteome.
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between the different proteomics studies on CVF. The
fractions of immunological and extracellular proteins
are lower in the ‘larger’ studies of Shaw et al. [44] and
Zegels et al. [22] (respectively 11.72% and 12.57%) as
compared to the ‘smaller’ studies from Pereira et al. [43]
and Dasari et al. [42] (respectively 18.95% and 19.61%).
The same holds for the extracellular fraction [22]. In a
recent experiment, we identified 706 proteins from
which 267 proteins were new identifications (unpub-
lished results). Only 5.33% of these proteins fell into the
“immunity and defense” functional category, which is
much lower than was found in any other study (see
above).
A general trend is noticeable in proteomic analysis of
CVF towards the identification of increasing quantities
of different proteins using comprehensive techniques.
This tendency was facilitated by the drastic technologi-
cal evolution which proteomics has undergone the last 5
to 10 years. The development of sensitive, high resolu-
tion mass spectrometers with fast scan rates allows the
coverage of dynamic ranges up to six orders of magni-
tude. The dynamic range of the experimental setup was
further enhanced by improving HPLC separation prior
to mass spectrometric analysis (e.g. increased sensitivity
and reproducibility and use of columns with higher
peak capacity). Moreover, progress has been made in
multidimensional separations in order to further
increase the peak capacity. All together, the technologi-
cal developments in proteomics resulted in analytical
platforms which can now cover larger parts of the pro-
teome [63]. This is also reflected in the studies on the
CVF proteome where increasing numbers of proteins
were identified with the contemporary techniques
(Figure 3).
It is the common opinion that by digging deeper into
the CVF proteome, more potential biomarkers could be
isolated and multi-protein expression profiles can thus
be analyzed. With this reasoning however, one must
take into account some inherent disadvantages of large
proteomic studies. In Figure 3, the total number of pro-
teins identified and the numbers of immunological or
extracellular proteins (which are characteristic for the
CVF proteome) in the different studies are plotted.
From this, it is clear that while the total number of
identified proteins increases exponentially, the immuno-
logical and extracellular fraction only increases linearly.
This graph indicates therefore that the majority of newly
obtained identifications have no known function or their
function in the CVF is questionable or not biologically
relevant. We therefore hypothesize that although large
number of proteins are identified in the recent sensitive
large proteomics studies, the vast majority of newly
identified proteins are most likely part of the variable
proteome which consist mainly of non-characteristic
proteins. Thus by digging deeper into the CVF pro-
teome, the challenge of identifying specific biomarkers
among this large amount of non-characteristic proteins
increases significantly. Optimization of sample collection
methods to minimize cell lysis may be a step forward to
reduce the amount of non-characteristic proteins. On
the other hand, epithelial cell shedding is an essential
process in the removal of pathogens and many other
factors (e.g. hormonal regulation, non-oral contracep-
tives) will always cause cell disruption and lysis, prior to
sample collection.
Cervicovaginal fluid biomarkers with potential
clinical applications
The lower genital tract is exposed to a large microbial
pressure and forms an important entry gate for a wide
variety of pathogens such as Candida spp., Trichomonas
vaginalis, human immunodeficiency virus (HIV) and
human papillomavirus (HPV). In contrast, the upper
female genital tract is believed to be sterile under nor-
mal circumstances. Nevertheless, pathogens such as
Neisseria gonorrhoeae and Chlamydia trachomatis can
occasionally ascend from the lower to the higher genital
tract and can cause pathogenic conditions such as pelvic
inflammatory disease (PID). The clinical impact of these
infections may not be underestimated since they can
lead to serious conditions such as preterm birth,
increased susceptibility to sexually transmitted infections
(STI), infertility and cancer [1,2]. Therefore, early diag-
nosis is essential for the successful treatment of the
underlying pathology and to prevent irreversible compli-
cations. For this reason, there is a high demand for new
diagnostic tools, such as biomarkers, which allow for
better and earlier treatment of gynecological pathologies
[17].
In the following paragraphs some important infection-
correlated pathologies are discussed for which potential
biomarkers were discovered using human CVF samples.
Table 2 gives an overview of these potential biomarkers.
Human papillomavirus infection and cervical cancer
HPV is one of the most common sexually transmitted
infections. It is estimated that 70-80% of the sexually
active female population will acquire HPV before the
age of 50 [64] and 80% of the HPV-infected patients
will spontaneously clear the virus within 2 years [65,66].
HPV is associated with high morbidity and mortality
worldwide, since it can cause precancerous lesions and
cervical cancer. The latter is the second most observed
cancer in women and is caused for nearly 100% by
HPV-infection [67]. There are more than 150 HPV
types and almost 40 of them infect the anogenital
region. HPV can be divided in low and high risk HPV.
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The most common high-risk types are 16, 18, 45, 31
and 33). Cervical cancer is mainly caused by an infection
with a high risk type [68]. Infection of squamous or
glandular epithelial cells with HPV causes morphological
alterations which lead to the formation of squamous or
glandular intra-epithelial lesions. The severity of this
precancerous condition depends on the extent, the site
as well as on the depth of the infected epithelial layer
[67,69].
Because of the high prevalence, the severe conse-
quences and the lack of a good treatment of advanced
cervical carcinoma, the emphasis of managing this con-
dition lies on prevention and diagnosis in a stadium as
early as possible. The recently introduced prophylactic
HPV vaccination will prevent about 98% of infections
with HPV 16 and 18 but will also in part, due to so
called cross protection, prevent HPV 31 (89%), HPV 33
(82%), HPV 45 (100%) and any high risk HPV type 16/
18/31/33/35/39/45/51/52/56/58/59/66/68 (70%). As
such, the HPV vaccination will prevent about 70 - 80%
of all cervical cancers [70,71]. Recently, clinical trials
started with a nine-valent HPV vaccine which could
potentially prevent 90% of all cervical cancers but infor-
mation on this topic is still scarce. Therefore, it is still
needed to screen women between the ages of 25 and 65
on a frequent basis by means of a Pap test (liquid based
cytology) preferable with a type specific HPV testing.
Screening using the classical Pap test has led to a con-
siderable reduction of the mortality, yet there are still
some notable shortcomings. The current screening is (1)
labour intensive, (2) difficult to automatize, (3) vulner-
able to inter- and intra-observer variability and (4) is
not very sensitive [65,72,73]. Moreover research has
demonstrated that despite intensive screening cam-
paigns, the coverage in most Western countries stays
low (e.g. 59% in Belgium) [74]. Testing for the presence
of HPV DNA or RNA will increase the sensitivity, but it
cannot predict progression to intra-epithelial lesions and
eventually cervical cancer.
Taking all the above into account, this implicates that
alternative screening methods (e.g. based upon protein
biomarkers present in CVF) with both a higher sensitiv-
ity and specificity are needed. The identification of a
highly sensitive and specific protein biomarker from
CVF would mean a substantial improvement both on
medical and social-economical field because an accurate
biomarker for the detection of cervical neoplasia will
result undoubtedly in a more precise and efficient
screening which correlates with a further reduction of
precancerous morbidity and cervical cancer morbidity
and mortality [75]. Additionally, proteomic analysis of
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Page 10 of 23Table 2 Overview of potential CVF protein/peptide biomarkers for different diseases, conditions or statuses of the
female genital tract
Condition or patient status Potential CVF protein/peptide biomarker Reference Also found in larger proteomic
studies
HPV infection and cervical
cancer
Il-6 [190,191]
Il-8 [190,191]
IL-12p40n [65,192]
IFN-g [65,192]
Il-10 [65,192]
TGF-b1 [65,192]
TNF-a [65,192]
Il-1b [65,192]
Il-5 [193]
Anti HPV IgG [194,195]
Anti HPV IgA [196]
antigalactosyl (a1®3) galactose antibodies [197]
HIV resistance
Anti-HIV IgA and IgG antibodies [103-113]
RANTES [100,114]
Bacterial Vaginosis
antimicrobial peptides (e.g. SLPI, defensins, lysozyme
and lactoferrin)
[142-147] [14,22,36-38,40,42-45]
IL-1b [198-208]
IL-8 [198,201,204,207,209-211]
IL-10 [120,128,210]
IL-4 [198,210]
Preterm Birth
fetal fibronectin [162-168] [36,43,44]
C-reactive protein [212]
interleukin-6 [212-217]
interleukin-8 [215,216,218-220]
interleukin-1b [220]
granulocytic elastase a1-antiprotease [221,222]
prolactin [223]
sialidase [224]
monocyte chemotactic protein 1 [225]
insulin-like growth factor-binding protein-1 [226,227] [43]
defensins [142] [22,36-38,42-44,147]
lactoferrin [228] [14,22,36-38,42-44]
matrix metalloproteinases [212] [36,42-44]
b-human chorionic gonadotrophin [229,230]
PPROM
b-human chorionic gonadotropin [178,183,231-236]
insulin-like growth factor binding protein-1 [226,227,237-246] [43]
diamine oxidase [240,247-251]
active ceruloplasmin [252] [36,37,42-45]
fetal fibronectin [250,253] [36,43,44]
C-reactive protein [254]
a-fetoprotein [183,231,250,255-259]
prolactin [231,260-263]
placental a-microglobulin-1 [184]
interleukin-1 receptor antagonist [46] [22,40,42-45]
The table lists CVF protein biomarkers identified in non-proteomic studies using mainly antibody-dependent techniques (e.g. ELISA). Last column shows, when
possible, the proteomics studies in which these biomarkers were also detected. Biomarkers identified the proteomics studies are not presented.
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patients after treatment [76] or to prognostic biomarkers
which could predict the evolution from precancerous
low-grade squamous intra-epithelial lesions (LSIL) to
either high-grade squamous intra-epithelial lesions
(HSIL) or clearance of the lesions. These prognostic bio-
markers would benefit the screening method as the
number of follow-up patients could be reduced signifi-
cantly (up to 80%). Also, identification of proteins
involved in the clearance of the virus could be of major
importance for the future development of new antiviral
therapies.
However, only few studies are performed on human
CVF for the identification of such biomarkers as most
large proteomic studies were restricted to cervical
cancer tissue [77-82]. Studies which used CVF as sam-
ples for their analysis did not use antibody-independent
proteomics techniques, but mainly ELISA or Western
blotting, and were therefore restricted to the analysis of
a small number of proteins taking part in the immune
response against HPV. In table 1, several proteins are
listed which are associated with HPV infection, cervical
cancer and cancer prognosis and progression. Neverthe-
less, these proteins are primarily correlated with the
prognosis of the disease but do not allow for a sensitive
and/or specific prediction of healthy women which are
at high risk. It is our opinion that such potential bio-
markers have the highest chance to be discovered in a
proteome wide approach, using proteomics techniques
on a large number of samples.
HIV-resistance
More than 25 million people have already died because
of HIV since the discovery of the virus in 1981, making
it one of the most disastrous epidemics in human his-
tory. In 2008, 33.4 million people were living with HIV
and 2.7 million people got infected by the virus [83,84],
mainly due to heterosexual HIV transmission [84-86].
One of the largest problems remains the absence of an
effective therapy. Also, despite the enormous efforts
made, the development of a prophylactic AIDS-vaccine
will likely not be available in the recent years to come
[87]. This leads to an increased importance for microbi-
cides (i.e. chemical entities that can prevent or reduce
transmission infections) which can be applied locally
(e.g. vaginally or rectally) as a potential alternative
approach in HIV prevention [9,88,89]. However, the effi-
cacy trials often gave rise to unsatisfactory results like
enhanced HIV-transmission, toxicity and immune acti-
vation [41,90]. To overcome these problems, new
powerful microbicides need to be identified which pre-
ferentially occur naturally and act under these in vivo
circumstances against sexually transmitted HIV infec-
tions [41].
Analysis of samples obtained from exposed seronega-
tive individuals (ESNs) may yield such new, therapeuti-
cally relevant microbicides. ESNs are individuals (<5%
of the population) from high-risk cohorts that remain
IgG-seronegative despite frequent HIV-exposure [91]
and therefore show a certain degree of in vivo HIV-
resistance. ESNs are found between commercial sex
workers, hemophiliacs receiving HIV-contaminated
blood, healthcare workers, children from HIV-infected
mothers, intravenous drug users or they are the serone-
gative partner in a discordant couple [92-94].
Some biological factors are already associated with the
ESN-status. Those include innate host factors like muta-
tions of chemokine receptors (e.g. CCR5-Δ32), the upre-
gulation of chemokines such as RANTES, MIP-1a and
-1b due to genetic polymorphisms, specific human leu-
kocyte antigen haplotypes (e.g. HLA-B*27 and HLA-
B*57), natural killer cell activity regulated by killer Ig
like receptor/HLA interaction, the presence of autoanti-
bodies and/or alloantibodies and more efficient immu-
nological effects after toll like receptor stimulation. Also,
particular properties of the acquired immune system of
the host show correlation with the ESN-status such as
cytotoxic and helper T lymphocyte responses against
HIV epitopes, humoral immune responses with the pro-
duction of neutralizing anti-HIV antibodies and the pre-
sence of soluble inhibitory factors [92-99].
Generally, none of these associations alone can be
held fully responsible for the observed HIV-resistance,
and many unknown factors are yet to be discovered
[41]. Current studies speculate that ESNs inhibit HIV-
infection in a very early phase of viral transmission
[100,101]. HIV-resistance may for example result from
mechanisms present at the viral entry gate, which often
is the mucosa of the female genital tract. Among these
mechanism, proteins or peptides present in CVF of
ESNs may play an important role [41].
Several studies on female ESNs have used CVF as
choice of sample for analysis. It has been described that
cervicovaginal lavages from ESNs sometimes contain
gp41 and p24 HIV antigens, suggesting that there was an
HIV exposure, but no seroconversion could be detected
[102]. Anti-HIV IgA and IgG antibodies were detected in
CVF obtained from heterosexual ESN women [103-113].
Additionally, it has been shown that levels of the HIV
suppressive b-chemokine RANTES levels were signifi-
cantly higher in CVF from ESNs [100,114]. Moreover,
CVF contains proteins/peptides with intrinsic anti-HIV
activity such as defensins, lactoferrin, lysozyme, cathelici-
din and SLPI [22,92,115,116]. The proteomic study from
Venkataraman et al. on CVF showed that the cationic
fraction of CVF has natural anti-HIV activity. The
authors speculated that this activity is the result from a
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[38]. It is possible that differences in protein expression
patterns of those anti-HIV proteins/peptides may result
i nt h eo b s e r v e dH I V - r e s i s t a n c eo fs o m eE S Nc o h o r t s .
However, conventional techniques such as ELISA or
Western blotting are incapable to analyze complex differ-
ential patterns from multiple proteins. Therefore, proteo-
mics studies may aid in the elucidation of these factors.
Indeed, recently, Burgener et al.[ 3 5 ]s t u d i e dH I V -
resistance in ESN persons and used 2D-DIGE as a quan-
titative proteomics technique to compare protein
expression patterns from ESNs with those from control
groups. The authors identified 16 differentially expressed
proteins with different biological functionalities such as
protease inhibitors (e.g. serpin B3/B4/B13/B1 and cysta-
tin A) and proteins with an immunological role (e.g.
protein S100A7 and complement component 3). Iqbal
et al. [41] used surface enhanced laser desorption ioniza-
tion (SELDI)-TOF mass spectrometry for the analysis of
the CVF proteome of a large population of ESNs and
control groups. The authors demonstrated that elafin/
trappin-2 is significantly upregulated in ESNs [41]. Ela-
fin/trappin-2 is an antiprotease from the whey acidic
protein (WAP) family, of which SLPI is also a member,
that can be found in CVF (see above). It functions as an
anti-inflammatory protein by counteracting proteases
secreted by neutrophils. Due to the cationic nature of
elafin/trappin-2 it can destabilize bacterial cell walls or
viral envelopes, thus exerting a certain degree of antimi-
crobial activity [117]. At about the same time, elafin/
trappin-2 was identified as a new anti-HIV factor which
directly interacted with the virus for its inhibition, thus
making it an interesting protein for further investigation
[118]. Hence, both studies confirm each other, thereby
increasing the possibility that elafin/trappin-2 effectively
plays a significant role in HIV-resistance. Surprisingly,
this protein was not among the differentially expressed
proteins in the study of Burgener et al. [35] where a dif-
ferent technique was used (2D-PAGE vs. SELDI). These
results indicate once again that different proteomics
techniques complement each other and are necessary to
uncover further other CVF proteins correlating with
in vivo HIV-resistance. Moreover the use of samples
obtained from dissimilar ethnological cohorts may yield
different results as it becomes more evident that several
different mechanisms may lead to HIV-resistance.
Bacterial vaginosis
Bacterial vaginosis (BV) is a frequently observed condi-
tion by which the normal vaginal flora is disrupted.
The prevalence of this pathology in Europe is 5-30%.
Other geographical regions, especially those with a
lower socio-economic status like the sub-Saharan part
of Africa, show higher prevalences (over 50%)
[119-121].
BV is a non-inflammatory condition, although it is
often classified as a vaginitis, characterized by the loss
of hydrogen peroxide forming Lactobacillus spp. (e.g.
L. crispatus, L. acidophilus, L. rhamnosus) and by an
increased growth of anaerobic species (e.g. Atopobium
vaginae, Mobiluncus spp., Prevotella spp.). Also, whereas
a healthy vaginal flora contains only few different and
predominantly Lactobacillus species, the vaginal flora
correlated with BV is polymicrobial in nature [119]. The
question remains whether the loss of the Lactobacillus
spp. is due to the introduction of a yet unknown factor
which results in the passive growth of the anaerobic
species or, vice versa, whether there is a massive influx
of anaerobic species which eradicate the lactobacilli
[122,123]. Although BV is not classified as a sexually
transmitted infection, the condition has several features
indicating that it may be caused by an exogenous source
[124]. Nevertheless, the etiology of BV is not yet well
understood.
BV can lead to severe health problems and early diag-
nosis can prevent serious complications. A significant
correlation exists between the presence of BV and pre-
term birth and it has been shown that treatment of BV
may reduce the risk on preterm birth [119,120,124,125].
BV has also been linked with PID, miscarriage [124] and
infertility [126] increased susceptibility for HIV and
HPV [124,127-132], herpes simplex virus type 2
[133-135] and other lower genital tract pathogens [120].
The mechanism by which BV leads to those pathologi-
cal conditions is not well known. It has been suggested
that increased susceptibility to HIV and genital tract
infections may be attributed to the production of succi-
nate by anaerobes, which can inhibit neutrophilic func-
tion [136]. Also, some anaerobes produce sialydases
which effect immune cells (e.g. inhibition of phagocytes)
[137] and have mucinase activity [138]. Additionally,
Ureaplasma urealyticum can produce proteases which
can cleave IgA [139]. It has also been shown that CVF
from some seropositive and seronegative women with
BV has the capability to enhance HIV replication in
vitro. This activity has been attributed to a certain solu-
ble and protease sensitive HIV-inducing factor (HIF)
which has not been identified yet. The general opinion
hypothesizes that HIF is a mixture of products derived
from BV associated bacteria on the one hand and host
factors such as certain cytokines (e.g. myeloid-related
protein 8) on the other hand [140,141].
No large proteomics studies have been performed on
CVF from women with BV, but several ELISA experi-
ments were executed. The results show that BV CVF
samples are deficient in antimicrobial activity due to
lower expression levels of several antimicrobial peptides
such as SLPI, defensins, lysozyme and lactoferrin
[142-147]. Furthermore, many studies also detected
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cytokines correlated with BV (see table 1). These studies
suggest that BV leads to the disruption of the normal
innate and adaptive immune response and induces an
inflammatory environment in the lower genital tract
which can lead to increased susceptibility for HIV and
other genital tract infections [120,128,148]. However,
since only antibody dependent studies were performed,
analysis was limited to a few well characterized proteins.
Nevertheless, little is known about expression differ-
ences of multiple proteins, which may include new or
unexpected ones. Differential analysis of the CVF pro-
teome using proteomics approaches, may yield more
information about the perturbation of the female genital
tract immunity due to BV and further clarify the etiol-
ogy of the disease.
Preterm Birth
As mentioned before, conditions such as bacterial vagi-
nosis and other infections of the female genital tract are
the main cause of preterm birth. Other risk factors
include multiple pregnancy or uterine contractions of
cervical incompetence. Nevertheless, a significant part of
the observed preterm births are idiopathic, indicating
that the etiology of preterm birth is still not well under-
stood [149-151].
Preterm birth, defined by the WHO as birth occurring
before 37 completed weeks of gestation, is a major
cause of neonatal morbidity and mortality [152,153].
Recent reports estimate the incidence of preterm birth
9.6% worldwide, with the highest rates in Africa and
North America (respectively 11.9% and 10.6%) and the
lowest in Europe (6.2%). The impact of preterm birth on
the health of the neonate can be very severe on short-
term (e.g. respiratory stress syndrome, brain injury) as
well as on long-term (e.g. chronic lung disease, sensory
deficits, learning disabilities) thus affecting the child’s
development and the physical and psychological health
of the infant’s environment [153-155].
Preterm birth is difficult to treat, therapy is often inef-
ficient because the underlying cause is seldom deter-
mined and the diagnosis is frequently made too late
[154,156-159].
Due to the clinical importance of preterm birth, pre-
vention strategies need more attention in the manage-
ment of this condition [157,160]. Currently this is
achieved by assessing the risk of the occurrence of pre-
term birth using several parameters or markers. History
of preceding preterm birth is the most important risk
factor and may relate to cervical anatomical problems.
In addition, presence of any of the causal factors men-
tioned before drastically increases the chance on pre-
term birth [149,161]. CVF fetal fibronectin (FFN)
concentrations are also correlated with the risk for pre-
term labour/birth, but quantification of CVF FFN alone
has not enough discriminatory power [162-168]. Com-
bination of this test with cervical ultrasound mea-
surements however showed better correlations
[166,169-172]. Several other markers have been corre-
lated with the risk on preterm birth/labour, all of which
are summed in table 1. Nevertheless, low specificity and
precision are inherent to these primary predictors.
Therefore, new markers need to be identified which
allow for more precise and specific risk assessment
[149,157]. Besides, these markers may give additional
information about the etiology and/or pathophysiology
of this condition which can be used in the development
of alternative therapies [43].
As mentioned before, Pereira et al.[ 4 3 ]i d e n t i f i e d
potential biomarkers for preterm birth/labour in a pro-
teomics study. These included fibronectin, several S100
proteins (calgranulin A, B and C), acute-phase reaction
proteins (annexin A3, a-1-antitrypsin and a-1-acid gly-
coprotein) and proteins involved in cellular organization
and motility (e.g. profilin-1, thymosin b-4, rho GDI 2).
Recently, the same research group looked for biomar-
kers for intra-amniotic infection, which is an important
risk factor for preterm birth and may lead to severe
neonatal pathologies. 170 CVF samples were classified
in three different groups: intra-amniotic infection and
preterm birth; no intra-amniotic but preterm birth; no
intra-amniotic infection and preterm labour. The
samples underwent 2D-LC (SCX/RP) combined with
ESI-QTOF mass spectrometry. Quantification and
comparison of protein expression levels between the
three groups was achieved by spectral counting. The
authors found 26 potential biomarkers for intra-amnio-
tic infection (statistical significant expression differ-
ences), which included acute phase reactants (e.g. a1-
antitrypsin), immune modulators (e.g. lysozyme and
a-defensin), amniotic fluid proteins (e.g. haptoglobin)
and extracellular matrix-signaling proteins (e.g fibro-
nectin). 13 of those were confirmed as potential bio-
markers for intra-amniotic infection in immunoassays
performed on the 170 samples. Using four of these
proteins (a1-acid-glycoprotein, insulin-like growth fac-
tor binding protein-1, calgranulin C and cystatin A) in
a logistic regression model, a fairly accurate differentia-
tion between patients with intra-amniotic infection and
those without intra-amniotic infection could be
obtained. Although further clinical validation of these
potential biomarkers is required, these results may lead
to the development of new diagnostic assays for intra-
amniotic infection. Also, the authors showed that the
etiology of preterm birth caused by intra-amniotic
infection is different than preterm birth without
infection [52].
Shah et al. [53] used the stable isotope labeling by
amino acids in cell culture (SILAC) technique to label
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(respectively End1 and Vk2). After the labeling process,
a labeled cellular secretome (i.e. a “standard secretome”)
from vaginal and endocervical cells could be purified.
CVF proteins can then be relatively quantified in test
samples in a precise and accurate way by means of this
“standard secretome” and multiple reaction monitoring
(MRM). This technique is called stable isotope labeling
proteome (SILAP). Normally, MRM requires the addi-
tion of labeled synthetic proteotypic peptides, which are
often very expensive, but the use of SILAP has the
advantage that the labeled “standard secretome” can be
used instead. Nevertheless, since the concentration of
the peptides in the “standard secretome” is not accu-
rately known, it is not possible to absolutely quantify
proteins in the test samples. A set of 15 candidate CVF
biomarkers were thus relatively quantified and expres-
sion profiles were compared between healthy controls
and preterm birth cases. This resulted in three proteins
which were significantly upregulated (desmoplakin iso-
form 1, stratifin and thrombospondin), but the possible
role of these proteins in the pathogenesis of preterm
birth is not yet known [53].
Preterm premature rupture of membranes
Many studies have been performed on preterm prema-
ture rupture of membranes (PPROM) which is an
important risk factor of preterm birth (see above).
PPROM is defined as “rupture of the fetal membranes
prior to onset of labour in a patient who has a gesta-
tional age of less than 37 weeks” and has an incidence
of 3-5% of all pregnancies [173-178]. A number of CVF
proteins and peptides are associated with this
condition and are listed in table 1. Also other non-pro-
tein markers are associated with PPROM such as lactate
[173,179,180], urea [181] and creatinine [181-183]. How-
ever, no differential proteomics studies have been per-
formed focusing on this condition. Nevertheless, it can
be expected that, as is the case with the preterm birth
in general, the use of proteomic technology may result
in new insights in the etiology of PPROM and the isola-
tion of clinical applicable biomarkers.
Amnisure® International LLC (Cambridge, MA) has
developed the FDA approved AmniSure® ROM test for
the diagnosis of PPROM. This simple immunoassay
identifies placental a-microglobulin-1 which is abundant
in amniotic fluid (2000-25000 ng/ml), but almost unde-
tectable in cervicovaginal secretions (5-25 ng/ml). Only
in the case of PPROM, higher concentrations are detect-
able in CVF. Analysis of clinical application possibilities
of the test has shown a sensitivity of 99% and a specifi-
city of 88-100% [184,185]. This test is a good example
of the potential of CVF samples as biomarker sources
and their applicability in clinical diagnosis. Although the
test is still under investigation, the clinical use of such
non-invasive test may eventually replace traditional diag-
nostic methods [177].
Classical approaches versus new techniques
The vast majority of potential CVF biomarkers listed in
table 1 was identified and validated using antibody-
dependent classical approaches such as Western blotting
or ELISA. Only the last few years, the use of proteomics
as a new alternative technique for biomarker discovery
has gained more interest due to the evolution of techni-
ques such as chromatography and mass spectrometry
from low reproducible and highly specialized methods
to more user friendly, robust systems. The use of com-
prehensive proteome characterization and analysis has
the great advantage that a huge amount of proteins (at
least those which fall in the dynamic range of the
applied techniques) are under consideration as potential
biomarkers. Other techniques such as ELISA require the
use of antibodies, which may restrict investigation to
those biomarkers for which antibodies are available and
purchased. Additionally, antibody-based techniques are
sometimes incapable of discriminating between different
subtle protein forms, whereas mass spectrometry can
solve this problem. For example, it has been published
that two a-defensins (HNP 1 and 2) are very sensitive
and specific biomarkers for intra-amniotic infection.
However, using ELISA, it is not possible to discriminate
between HNP1 and 2 due to high sequence similarity.
In contrast, due to the mass difference between HNP1
and 2, mass spectrometry can differentiate between both
forms [186,187].
Nevertheless, this does not imply that proteomics is
superior to antibody dependent methods in biomarker
discovery experiments and makes them completely obso-
lete. Indeed, antibody-based validation is often required
to confirm proteomics results. Also, as can be seen in
table 1, a large part of the biomarkers identified in non-
proteomics studies, are not identified in any of the CVF
proteome characterization studies mentioned above.
Therefore, techniques such as Western blotting or ELISA
are rather complementary then inferior to proteomics.
Conclusions
CVF has great potential as a source for biomarkers for
pathologies of the female genital tract. Many details
about the complex physiology of the female genital
tract, even under normal circumstances, are yet
unknown and only few proteomics studies have been
executed on this topic [39,46,47]. Nevertheless, CVF
may yield a wealth of information about the “normal”
functioning of the female genital tract and proteomic
analysis may improve our understanding of micro-envir-
onmental changes due to the influence of multifaceted
conditions such as menstrual cycle, age or pregnancy.
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(table 1), not many of the potential biomarkers find
their way towards a clinical application. Only the Amni-
Sure® ROM test for the diagnosis of PPROM, based
upon the detection of placental a-microglobulin-1, has
been further validated in clinical trials and is FDA
approved. The problem in the validation of biomarkers
and the subsequent development of biomarker based
diagnostic tests, often lies in the transition from discov-
ery to validation phase. Frequently, too little effort has
been made in setting up statistical relevant experiments
and important aspects such as sample size, inter- and
intraindividual and technical variabilities are often
underestimated or not well defined. This inevitably leads
to results which lack statistical power and to potential
biomarkers which generally do not survive further vali-
dation [153,178,188,189]. In order to obtain statistically
significant and practically useable highly specific and
sensitive CVF biomarkers, several steps must be under-
taken. 1) It is essential to analyze and characterize the
CVF proteome precisely to be able to define the physio-
logical environment in which experiments are conducted
[18]. 2) Also, the inter- and intraindividual variability
must be determined, which is critical in order to deter-
mine the number of samples needed to obtain statisti-
cally relevant results and to distinguish real biomarkers
from natural occurring biophysiological variations. So
far, although quantitative and comparative experiments
were performed on CVF, not much attention has been
given to the contribution of biological variation [16,24].
A good understanding of the effect of factors affecting
the proteome composition (e.g. age, use of contracep-
tives, menstrual cycle, etc.) is therefore essential and
should be taken into account during sample collection.
Additionally, the choice of control groups in the experi-
mental setup can have a drastic effect on the eventual
results. For example, some markers (e.g. fibronectin, C-
reactive protein, prolactin) for preterm birth are often
found in preterm premature rupture of membranes
(table 1). Nevertheless, markers for preterm birth which
were found to be highly specific, may be in fact low spe-
cific if PPROM patients were included in the control
group.
Up to now, most studies using CVF as clinical sam-
ples, used antibody dependent techniques such as
ELISA and Western blotting, although these are only
capable to provide very limited amounts of information
so that important data are inevitably missed. Neverthe-
less, many of these studies improved our understanding
of different pathologies and conditions. However, the
use of proteomic technology has the advantage to ana-
lyze many different proteins at the same time and can
yield large amounts of information. We strongly believe
that quantitative and comparative proteomic analysis of
the CVF proteome will yield new complementary
insights and information about the biophysiological nat-
ure of the female genital tract which may lead to further
progression in our understanding of gynecological
pathologies. All together, this may result in a better
management of these diseases and thus, hopefully, will
reduce associated morbiditya n dm o r t a l i t yf o rw o m e n ,
mothers and children.
Additional material
Additional file 1: Overview of all identifications obtained in
different proteomic studies on human CVF.
Additional file 2: List of proteins identified from CVF and cervical
mucus. Swissprot accession number, the protein name, cellular
localization and the different biological functions of the protein are
given. Yellow highlighted proteins were also identified in human
amniotic fluid, green highlighted proteins were identified in human
serum and orange highlighted proteins were identified in serum as well
as in amniotic fluid. Proteins marked with * are uniquely identified in
cervical mucus and not in any other study on human CVF.
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